Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

PowerPollen Receives Foundational Patent for Groundbreaking Pollen Storage Methodology

PowerPollen

PowerPollen, an agtech company improving crop pollination for increased agricultural productivity and profitability, has received U.S. Patent 12,245,587 for its groundbreaking process of using solid particulates blended with fresh pollen grains to protect pollen’s viability during storage. As the industry leader in commercial scale pollen collection, application and storage, PowerPollen’s IP strategy has been a key part of protecting their innovation while rapidly scaling to support global seed companies and farmers since the company was founded in 2015. PowerPollen collects, preserves and applies pollen to corn, wheat, rice, and other important crops, eliminating the previously required dependency on natural pollen shedding to pollinate female plants. This process enables the ability to more reliably and cost-effectively produce high-quality seed farmers plant for crops. Corn, rice, wheat and barley rank as the top four grain crops grown globally. This patent is part of a one-of-a-kind portfolio of intellectual property PowerPollen has secured in their pursuit to increase the productivity, profitability and sustainability of modern agricultural practices. “Our initial key discoveries more than a decade ago – and our ongoing innovation since – has enabled PowerPollen to scale our unique pollination tech stack of collection, storage and application to commercial levels in agriculture—helping farmers and seed production partners increase yields without increasing other inputs,” said Jason Cope, Chief Intellectual Property Officer, PowerPollen. “Our discoveries changed the previously held notion that row crop pollen was not capable of being stored for any duration. The ripple effect can clearly be seen by the consistent yield improvements in fields that PowerPollen has treated with stored pollen.” Achieving Production and Sustainability in Modern Agricultural Practices In 2015, PowerPollen began looking for ways to improve in-field crop pollination by collecting pollen and storing it for targeted application. In their discovery process, the greatest problem they encountered was that pollen tends to form large clumps when stored, which results in a rapid decline in pollen health. “We theorized that when a pollen grain dies, its walls lose integrity and the contents of the dead cell leak out, contacting other pollen grains in the batch being stored,” Cope said. “This causes adjacent pollen grains to die, resulting in the large clumps of dead pollen cells.” PowerPollen created a unique, cost-effective production process that blends fresh pollen with different materials that separate the live pollen grains from each other. This now patented process prevents the live pollen grains from contacting any material leaked from dead pollen grains, thus dramatically extending and prolonging the pollen’s viability. Today, PowerPollen holds the most patents for pollination-based technology, crop application and related innovations, based on over a decade of intellectual data and discovery and more than eight years of commercial field data and ongoing innovation. Because of its novel technology and the founders’ understanding of marketplace realities, IP strategy has been a critical part of the business to usher in the best technology advancements for customers. Patent Reinforces PowerPollen's Leadership in Pollination Technology for Agriculture “Seed crop producers today use incredibly innovative breeding techniques yet risk it all with pollination methods that haven’t changed for generations,” Cope said. “With this patent claim, we continue to execute our IP strategy focused on the foundational building blocks of pollination-enabling technologies – and advancing this innovation across crops and geographies at the pace, scale and reliability critical to advancing higher-yield and climate-resilient food production.” Seed industry partners already look to PowerPollen’s ability to practice on-demand pollination even within fields that are planted in the normal male to female row ratio. Pollination efficiency is the key rate limiting factor for yield and kernel quality. Further, producers can improve their seed purity by intentionally applying quantities of desirable pollen, which out competes undesirable pollen. By ensuring yield, quality and purity are all maximized, PowerPollen can generate significantly more value per acre. PowerPollen’s technology will be used on thousands of acres again this season across the U.S., with expansion planned globally. Customers interested in a demo or learning more can contact PowerPollen.com. PowerPollen offers a breakthrough, scalable technology to collect, preserve and apply pollen on-demand to help improve the productivity, profitability and sustainability of modern farming practices. Following multiple seasons of year-round field trials, PowerPollen’s patented pollination technology increases yield and improves the quality of commercial hybrid corn seed production. The company has applied its technology across thousands of commercial acres over the past several years. PowerPollen is headquartered in Iowa with additional research operations in Puerto Rico and Texas. Learn more about how PowerPollen’s on-demand pollination technology works at www.powerpollen.com. Contact Details AgTech PR Jennifer Goldston jennifer@agtechpr.com Company Website https://powerpollen.com

May 06, 2025 08:30 AM Central Daylight Time

Image

Nuvectis Pharma's NXP900: Could This Revolutionary Cancer "Inactivator" Transform Oncology Treatment?

Global Markets News

Investors seeking the next breakthrough in precision oncology may want to take note of Nuvectis Pharma (NASDAQ: NVCT)*, a clinical-stage biopharmaceutical company developing, among other candidates, NXP900 - which a a new analysis is describing not merely as a cancer inhibitor, but a complete cancer pathway "inactivator." The new analysis, published on notable investment newsletter “ Truffle Pigs ”, provided a comprehensive review of Nuvectis Pharma’s NXP900. Beyond Traditional Inhibition According to the Truffle Pigs blog, NXP900 represents something entirely new in cancer treatment. Unlike traditional kinase inhibitors that merely slow cancer signaling, NXP900 is characterized as the "first SRC kinase inactivator" - a distinction that could prove crucial in the fight against resistant cancers. The analysis highlights that NXP900 functions as a "type 1.5 inhibitor" that locks the SRC kinase in its inactive state, effectively shutting down all cancer signaling pathways and keeping them disabled between doses. This complete inactivation mechanism potentially offers a significant leap beyond current therapies. Promising Clinical Data Recent data presented at the 2025 American Association for Cancer Research (AACR) meeting appears to support this thesis. According to the analysis, NXP900 demonstrated: Perhaps most intriguing were results showing that when combined with AstraZeneca's blockbuster drug osimertinib (Tagrisso), NXP900 demonstrated significant tumor regression and extended tumor control even after treatment ended - suggesting potential for durable responses or even complete responses in certain patients. Dual Market Opportunity The analysis notes two major market opportunities for NXP900: Single-agent therapy for SRC/YES1-driven tumors, potentially addressing approximately 20,000 lung cancer patients annually Combination therapy for overcoming acquired resistance to targeted drugs like osimertinib (EGFR) or lorlatinib (ALK), potentially addressing up to 70,000 non-small cell lung cancer patients annually While established companies like AstraZeneca generate nearly $7 billion annually from Tagrisso targeting approximately 20,000 new EGFR-mutated patients each year, Truffle Pigs' analysis suggests NXP900's broader applicability could potentially drive peak sales of $12-15 billion across various cancer indications. Investor Perspective With only 23 million shares outstanding and a current market cap of 219 million, Nuvectis represents a high-risk, high-reward opportunity typical of early-stage biotech. The company recently raised capital through a public offering of common stock, extending its cash runway into 2027 on what many would consider impressive terms given the market backdrop. Phase 1b trials targeting biomarker-selected cancers are expected to commence shortly, with potential clinical response data anticipated later this year.Notably, the original blog highlighted that that while the author held a position in Nuvectis Pharma (NASDAQ: NVCT), he was not compensated to write or publish the content. In other words, one might say that the author has “skin in the game”. As with all development-stage biotechnology companies, significant risks remain. analysis appropriately notes that as with all companies in the field - regulatory approval hurdles, high clinical failure rates, capital intensity, potential market competition, uncertain revenue streams, and broader economic factors all present considerable risks that investors should take into account when conducting their due dilligence. The full Truffle Pigs Blog post is available here: https://trufflepigs.substack.com/p/nuvectis-pharmas-nxp900-the-first Recent News From Nuvectis Pharma Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC Legal Disclaimer & Disclosure: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Wall Street Wire™, a promotional content network and platform serving issuers around the globa. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution is paid promotional content related to Nuvectis Pharma and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by Nuvectis Pharma prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Readers are advised to refer to the full original blog post mentioned in the report and the disclosures it may be subject to. Contact Details WALL STREET WIRE Editorial Desk media.globalmarkets@gmail.com

May 05, 2025 01:59 PM Eastern Daylight Time

Spring Bird Delivers Transit Buses to MTR for Use in Major Construction Shuttle Operations

Spring Bird

Spring Bird has delivered six heavy-duty New Flyer D40LF transit buses to MTR, providing dedicated shuttle support for a large-scale semiconductor fabrication plant construction site. The buses will be used to safely and efficiently transport construction workers across the expansive site, reflecting the growing demand for durable, high-capacity shuttle solutions in complex infrastructure projects. The multi-bus order, fulfilled over the past year through several transactions, underscores Spring Bird’s rising role as a trusted supplier of transit buses for industrial and operational shuttle services. According to Spring Bird founder Elliott Carson, the deal came together due to “competitive pricing, fast turnaround, and strong warranty support,” all of which aligned with MTR’s high standards and tight project timelines. “This partnership with MTR is a great example of what happens when two teams are aligned in purpose and professionalism,” said Carson. “MTR had a clear vision, high standards, and a fast-moving project — and we were proud to meet that challenge. Supporting their shuttle operations with dependable, work-ready transit buses is exactly what Spring Bird is built to do.” The buses underwent standard make-ready servicing and were delivered ready for immediate deployment. While not retrofitted with low-emission or advanced telematics systems in this case, the New Flyer D40LF platform offers reliable performance, ample standing room, and durability that outperforms most traditional coach or cutaway vehicles under demanding, repetitive shuttle conditions. “Transit buses are built for this kind of work,” said Thomas Hoskins, Director of Operations at Spring Bird. “You’re moving large numbers of people, constantly, in stop-and-go patterns, sometimes on rough or temporary roads. These vehicles are designed for all-day, every-day use. They can load quickly, handle tough environments, and just keep going.” Spring Bird’s Construction Shuttle Service program highlights several key benefits of using heavy-duty transit buses in worksite transportation: Dual-door boarding allows faster loading and unloading compared to coach buses or vans. Low-floor designs increase accessibility and reduce boarding times. Higher standing capacity allows more flexible loading based on shift schedules. Cost-efficiency comes from needing fewer buses and drivers to move more people in less time. For MTR, choosing Spring Bird also meant working with a team that understands the complexity of operational logistics. “We’re proud to support partners like MTR who are helping to build the future—literally,” said Carson. “Whether it’s a long-term city transit solution or a short-term industrial project, our goal is always the same: safe, smart, dependable transportation.” The deal also adds another chapter to the Carson family’s eight-decade history in the transit industry. Spring Bird, founded by Elliott Carson in 2020, is built on a legacy that dates back to 1943 when Dean Carson began providing local transit in Los Angeles. Today, that commitment to innovation, service, and reliability lives on in Spring Bird’s growing footprint across public and private transportation sectors. About Spring Bird Spring Bird is a premier provider of transportation solutions, specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Media Contact: For more information, visit https://springbirdbus.com or contact us at press@springbirdbus.com. ### About Spring BirdSpring Bird is a premier provider of transportation solutions specializing in the sale, leasing, and service of heavy-duty transit buses and motor coaches. Drawing from the rich Carson family legacy in the transportation industry, Spring Bird offers an inventory of high-quality buses from leading manufacturers and provides customized rehabilitation services, including minor repairs, major overhauls, and technological retrofitting. Dedicated to safety, innovation, and customer satisfaction, Spring Bird addresses the unique needs of cities, transit agencies, and private operators, ensuring reliable and efficient transportation solutions. Contact Details Media Contact press@springbirdbus.com Company Website https://springbirdbus.com

April 30, 2025 10:41 AM Central Daylight Time

Image

Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue

NTRB

Nutriband Inc. (NASDAQ:NTRB) is a pharmaceutical company with a specific focus on developing a portfolio of transdermal pharmaceutical products. The company’s lead product under development is AVERSA™ Fentanyl, which is on track to becoming the first-ever abuse-deterrent transdermal fentanyl patch. AVERSA Fentanyl is currently pursuing a 505(b)(2) registration pathway, which should make it eligible for a more expedited review. For context, AVERSA is Nutriband’s proprietary technology that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with the potential for abuse, like opioids. What makes AVERSA unique is its aversive agent coating, which leverages taste aversion to deter oral abuse and accidental exposure to transdermal opioid patch products. More than 70% of fentanyl patch abusers choose oral routes to abuse, so taste aversion addresses primary routes of abuse. That means AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. In one of the company’s recent major corporate milestones, Nutriband announced that it had received notification that its patent had been granted in Macao, which protects its AVERSA abuse-deterrent transdermal technology. The technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia, as well as two regions of China: Hong Kong and Macao. Interestingly, the company hasn't been structured to follow the typical biotech standard when it comes to time and cost. The company already has two revenue-generating subsidiaries, 4P Therapeutics and Pocono Pharmaceutical, along with Active Intelligence, which specializes in sports recovery products. Nutriband’s revenues keep its development burn at a minimum. The company also owns its manufacturing and clinical development capabilities, which significantly reduces its costs for AVERSA and other technologies. Most notably, Nutriband partnered with Kindeva Drug Delivery to develop AVERSA Fentanyl, which combines Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) that has a rich history in pharmaceutical innovation and manufactures millions of transdermal patches distributed worldwide. This strong partnership for AVERSA Fentanyl’s commercial development has led to significant progress in the abuse-deterrent patch’s development and manufacturing. Recently the two companies revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. At the same time, Nutriband revealed that it had signed an Associate Partnership agreement with Charlotte FC, which would be instrumental in helping build visibility for its brands, such as AI Tape. Management noted, “We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.’’ AVERSA’s addressable market is huge, depending on how you look at it. For instance, accidental fentanyl misuse is a growing problem, as illustrated by a recent report that revealed there had been 32 cases of accidental fentanyl exposure, which occurred, resulting in 12 deaths and dozens of hospitalizations, mostly involving young children. This is where the technology comes into play, as it significantly reduces the likelihood of accidental exposure to fentanyl for children. Furthermore, AVERSA Fentanyl is well aligned with the FDA’s Opioids Action Plan mission to expand access to abuse-deterrent formulations (ADFs) and to reduce the risks of misuse not just by the patient but also by other persons who obtain opioids. Upon approval of AVERSA fentanyl, the company expects that the FDA will consider requiring all fentanyl patches to be abuse deterrent, as was required for all oxycontin generics, which could potentially translate to more market share. To put the opportunity here into better context, consider this. According to Health Advances’ assessment, once approved by the FDA, AVERSA Fentanyl is expected to reach peak annual sales of about $200 million. The company believes that conservative pricing will be a key component of capturing and maintaining market share in addition to real-world data and marketing. According to the Health Advances’ report on AVERSA Fentanyl, Nutriband can expect to comfortably charge a 20% premium versus generics while maintaining insurance coverage and support, ideally capturing the market as the safest fentanyl patch in its class. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting LLC to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 30, 2025 07:00 AM Eastern Daylight Time

Roberts & Ryan Earns Prestigious VETS Indexes 5-Star Employer Award for 2025

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., a Service-Disabled Veteran-Owned broker-dealer, is honored to receive the 2025 VETS Indexes 5-Star Employer Award — one of the program’s highest distinctions. This award celebrates the firm’s strong and ongoing dedication to hiring, developing, and supporting veterans, military spouses, and members of the National Guard and Reserves. The VETS Indexes 5-Star Employer distinction is reserved for organizations that demonstrate a sustained and comprehensive approach to veteran employment, retention, and support. Roberts & Ryan joins a select group of top-performing employers nationwide that serve as role models for veteran-focused workforce development. “Roberts & Ryan has demonstrated exceptional support for veterans and the military-connected community, earning the organization one of the most prestigious awards possible in the VETS Indexes Employer Awards program,” said George Altman, president of VETS Indexes. “Roberts & Ryan is among the very best veteran employers, and its program can serve as a model for others.” Roberts & Ryan’s recognition highlights the firm’s ongoing efforts to support service members transitioning to civilian careers. As a veteran-founded company, Roberts & Ryan understands the unique strengths and experiences veterans bring to the workforce and actively integrates that perspective into its hiring practices, workplace culture, and community outreach. “As a Service-Disabled Veteran-Owned Business, supporting the military-connected community is part of our DNA,” said Edward D’Alessandro, CEO at Roberts & Ryan. “This award reflects our deep commitment to honoring those who serve and not just through employment, but through opportunity, growth, and lasting impact.” The VETS Indexes 5-star Employer award was granted on April 11, 2025 Recipients of the VETS Indexes Employer Awards are selected based on their responses to VETS Indexes’ groundbreaking survey, which examines the most important veteran employment metrics via a granular, objective, and data-focused questionnaire. There was no compensation paid or received for consideration of the award. To view the full list of 2025 VETS Indexes Employer Awards recipients, visit: https://vetsindexes.com/award-results-2025 About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $2.38 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Securities are offered by Roberts & Ryan Inc., member FINRA | SIPC | MSRB | NYSE | NASDAQ. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

April 29, 2025 09:10 AM Eastern Daylight Time

TempoPay Rx Launches to Help Bridge the Prescription Drug Affordability Gap

TempoPay

TempoPay, a subsidiary of industry-leading healthcare financing and payments solutions provider PayMedix, today announced the availability of TempoPay Rx, a financing solution designed to address the growing trend in prescription drug non-adherence across the country. “We are excited to bring TempoPay Rx to the market and help create simpler and more affordable access to prescription medications for our clients,” said Tom Policelli, CEO, PayMedix. “We have seen how decreasing financial barriers to medical care has improved health outcomes for members and financial results for our employer clients. Expanding this to include pharmacy costs is the next logical step to help consumers get the care they need when they need it." With prescription drug prices rising at more than twice the rate of inflation, access and affordability for the nearly two-thirds (61%) of Americans who take prescription medications has become a serious concern. More than half (55%) of Americans report being worried about affording their prescription drug costs and nearly one-third (31%) have avoided taking medications as prescribed due to cost. TempoPay Rx is a card-based financing solution that provides enrolled employees with access to interest-free financing for prescription medications for themselves and their dependents. Employees of participating employers can receive the benefit with no credit checks or income requirements. The program offers interest and fee-free financing on a revolving basis, with flexible repayment terms made either via bank account or payroll deductions. TempoPay Rx members can access their benefit via the TempoPay app and can use either their mobile wallet or a TempoPay VISA® card to pay. PayMedix has been providing interest-free financing for in-network medical care for over 15 years. It recently completed a comprehensive study of the long-term benefits of its innovative payments solution on 45,000 active members in Wisconsin and found that not only was in-patient hospital care of PayMedix members lower than national averages by 8%, but employer medical trend increases were nearly 40% lower than the national average. “Making prescription medications more accessible by lowering the financing barriers ultimately brings the cost of healthcare down,” said Brian Marsella, President, PayMedix. “It’s a fact that medication non-adherence leads to worsening health, increased emergency room visits and hospital admissions, driving costs higher. Our clients have experienced enormous value from our medical care financing and have asked for expanded support for prescription medications. We’re proud to extend TempoPay Rx to all of our HPS employer groups this summer. Employers can further enhance this benefit with additional coverage for more funding or types of needs, ensuring comprehensive support for their employees.” TempoPay Rx will be available for all PayMedix employer groups in the HPS medical network at no additional cost beginning August 2025, with $500 in revolving funds to help subscribers afford prescription medications for themselves and their dependents. In addition to TempoPay Rx, interest-free financing for medical, dental and vision care is available through the TempoPay platform for any employer nationwide. More information can be found at www.tempopay.com. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With the TempoPay Visa® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. About PayMedix PayMedix is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. Contact Details TempoPay Hattie Ninteau hninteau@hps.md Company Website https://www.tempopay.com

April 29, 2025 09:00 AM Eastern Daylight Time

Consulta Remédios Selects Kevel’s Retail Media Cloud to Power its Next-Generation Advertising Platform

Kevel

Kevel, the leading provider of API-based retail media ad serving technology, today announced that Consulta Remédios, Brazil's largest medicine price comparison platform, has selected Kevel's Retail Media Cloud™ to power the development and enhancement of its in-house retail media network. This partnership marks a significant step in Consulta Remédios' digital transformation strategy, enabling the platform to offer more targeted and effective advertising solutions to its partners and underscores Kevel's growing presence in the Latin American market. By leveraging Kevel's cutting-edge technology, Consulta Remédios aims to create a bespoke advertising platform that aligns with its commitment to providing accessible healthcare information and competitive pricing to Brazilian consumers. The new retail media network will enable Consulta Remédios to offer its advertising partners more targeted and effective ways to reach customers while enhancing the user experience for its millions of monthly visitors. Working closely with the Kevel team, Consulta Remédios will leverage the Retail Media Cloud™ to create seamless integrations of retail media offerings into its digital strategies. This collaboration will emphasize enhancements to the user experience across both owned and off-site channels through personalization and relevant product recommendations, utilizing Consulta Remédios' unique first-party data. James Avery, Founder and CEO of Kevel, commented, "We're excited to support Consulta Remédios as they expand their retail media capabilities. Their decision to build their retail media network on our Retail Media Cloud™ demonstrates the value in our flexible API-first platform - empowering them to quickly launch customized ad campaigns, unlock rich first-party targeting and deliver highly personalized ad experiences. We're excited to help Consulta Remédios create a truly unique advertising experience that reflects their mission of making healthcare more accessible and affordable in Brazil." Key benefits of the Consulta Remédios-Kevel partnership include: Advanced Targeting: Consulta Remédios can now harness its rich first-party data to create AI-powered customer segments, enabling highly personalized advertising campaigns. Diverse Ad Formats: Kevel's platform supports a wide range of ad units, allowing Consulta Remédios to implement native ads, sponsored listings, and contextual displays seamlessly. Rapid Deployment: With Kevel's technology, Consulta Remédios can launch custom retail media campaigns in as little as 14 days, ensuring agility during peak health seasons and promotional periods. Data Compliance and Security: Kevel's industry-leading data compliance features allow Consulta Remédios to confidently use its customer data while maintaining strict privacy standards. Improved Advertiser ROI: More precise targeting and diverse ad formats are expected to significantly enhance returns for Consulta Remédios' advertising partners. Paulo Vion, CEO at Consulta Remédios, said, "At Consulta Remédios, we're always looking for innovative ways to improve our users' experience and provide value to our advertising partners. Kevel's Retail Media Cloud™ gives us the tools and flexibility we need to build a retail media network that's uniquely tailored to the healthcare industry. We're excited about the possibilities this opens up for our business, our users, and our advertising partners." The implementation of Kevel's Retail Media Cloud™, facilitated in collaboration with local partner ShopperMedia, is expected to be completed in phases over the coming months, with the first ad placements going live later this year. About Kevel Kevel is transforming the retail media space with its cutting-edge, AI-driven ad tech infrastructure APIs that power the Retail Media Cloud™. This groundbreaking solution combines the power of AI insights with API-based technology, allowing multi-brand retailers to build dynamic, customizable ad platforms while maintaining full control of their first-party data. With Kevel, retailers can deliver personalized shopper experiences, optimize ad targeting, and unlock predictive insights to stay ahead in an ever-evolving market. Kevel's mission is rooted in the belief that every digital retailer should have the tools to create their own tailored ad platform, comparable to industry leaders like Amazon. Harnessing the power of AI for data-driven decision-making, Kevel has helped leading brands such as Chewy, The Home Depot, Edmunds, Lyft, Delivery Hero, Sonae, Slickdeals, and others launch impactful retail media networks—fostering innovation and unlocking new revenue opportunities.Learn more about how Kevel is transforming retail media at www.kevel.com. About Consulta Remédios Consulta Remédios is Brazil’s leading pharmaceutical marketplace platform, helping millions of Brazilians find the best prices on both prescription and over-the-counter medications. It also stands out as the largest aggregator of small, medium, and large pharmacy retailers in the country. With a mission to make healthcare more accessible and affordable, the platform provides transparent information on pricing, drug interactions, and nearby pharmacy locations. It serves as an essential tool for both consumers and healthcare professionals, supporting more informed decisions when purchasing medications. Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com

April 29, 2025 09:00 AM Eastern Daylight Time

NAVEX One: Supporting HIPAA Compliance with Integrated Risk and Compliance Content

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management solutions, offers healthcare organizations the tools they need to meet rigorous data privacy and security requirements. As the regulatory environment grows increasingly complex, NAVEX announces that NAVEX One now delivers centralized policy management, employee training, and risk assessment solutions aligned with the Health Insurance Portability and Accountability Act (HIPAA) enabling simplified compliance. HIPAA establishes national standards to safeguard sensitive patient health information. To avoid costly penalties and protect patient trust, covered entities must adopt comprehensive administrative, physical, and technical safeguards. NAVEX One has long supported these efforts, offering content and capabilities that streamline compliance and strengthen privacy and security programs. “HIPAA compliance is a cornerstone of trust in healthcare. Organizations need a partner that not only helps them check the boxes but also actively supports their broader privacy and risk mitigation goals,” said A.G. Lambert, Chief Product Officer at NAVEX. “NAVEX One equips healthcare compliance professionals with the tools to develop sustainable, defensible programs that protect patient data and reduce regulatory risk.” NAVEX One empowers healthcare organizations to: Centralize and maintain privacy and security policies aligned to HIPAA. Train employees on HIPAA fundamentals and emerging risks. Assess risk and implement appropriate safeguards. Prepare for audits and investigations with robust documentation. Demonstrate ongoing compliance with automated tracking and reporting. By delivering these capabilities in a unified platform, NAVEX One streamlines HIPAA compliance, reduces administrative burden, and supports a proactive, organization-wide approach to privacy and risk management. “HIPAA requirements touch every part of an organization—from workforce training to incident reporting,” said Kyle Martin, Vice President of Risk Governance at NAVEX. “NAVEX One brings it all together in one auditable platform, giving healthcare leaders confidence they’re meeting requirements while building a strong company culture.” Learn more about NAVEX One HIPAA compliance software. NAVEX, the global leader in risk and compliance solutions, is trusted by thousands of organizations to strengthen compliance and proactively manage risk. Through the NAVEX One platform and unparalleled industry data and benchmarks, organizations are empowered to maximize the potential of their compliance and risk programs. Based in Lake Oswego, OR, with a global presence, NAVEX continues to shape the future of governance, risk and compliance. Visit our blog or follow us on LinkedIn, Facebook, and YouTube. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

April 24, 2025 01:22 PM Eastern Daylight Time

NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement

Global Markets News

NeuroSense Therapeutics (NASDAQ: NRSN)* is in active discussions with a global pharmaceutical giant for what CEO Alon Ben-Noon calls a potentially "transformative" partnership that could catapult the company's groundbreaking ALS therapy toward commercialization, according to a shareholder letter released today. The binding term sheet announced in December has progressed to advanced discussions for a "multinational partnership" that could deliver significant upfront capital and fully fund the upcoming Phase 3 trial. While initially expected to close in Q1, the complex deal's extended timeline suggests substantial terms are being negotiated, with Ben-Noon expressing optimism about an agreement that would mark "a true inflection point" for the company. Previous neurodegenerative disease partnerships have generated substantial value for biotech companies. GSK's 2021 deal with Alector included $700 million upfront and up to $1.5 billion in milestone payments, while Biogen's 2020 Denali partnership involved $560 million upfront with $1.125 billion in potential milestones. In 2024, Eli Lilly licensed QurAlis's preclinical ALS therapy for $45 million upfront plus up to $577 million in milestones—highlighting the pharmaceutical industry's willingness to invest heavily in promising neurological treatments. Investors have compelling reasons to watch NeuroSense closely as multiple catalysts approach. PrimeC, the company's novel ALS treatment, delivered remarkable Phase 2b results showing a 33% slowing of disease progression (p=0.007) and an impressive 58% improvement in survival rates compared to placebo. These potentially game-changing outcomes position PrimeC as one of the most promising ALS therapies in development. The company's dual-track commercialization strategy adds near-term revenue potential to its long-term pipeline value. While advancing toward a global Phase 3 trial set to begin in H2 2025, NeuroSense is simultaneously pursuing fast-track approval in Canada through a special regulatory pathway designed for life-threatening conditions with limited treatment options. Commercial forecasts project potential Canadian sales of $100-150 million annually—potentially providing significant revenue while the larger global program advances. Recent scientific validation came this month at the American Academy of Neurology Annual Meeting, where distinguished neurologists presented biomarker data confirming PrimeC's mechanism of action in targeting multiple disease pathways simultaneously. PrimeC's approach combines two FDA-approved drugs (ciprofloxacin and celecoxib) in a novel formulation designed to attack ALS through multiple pathways—inflammation, iron accumulation, and RNA regulation—giving it potential advantages over single-target therapies. The drug has received coveted Orphan Drug Designation from both US and European regulators. The ALS treatment landscape represents a significant commercial opportunity, with over 30,000 patients in the US and Europe and approximately 5,000 new diagnoses annually in the US alone. With limited effective treatments currently available, successful therapies command premium pricing and substantial market share. Upcoming catalysts include Canadian regulatory progress, potential partnership announcement, and Phase 3 initiation in the second half of 2025—each representing potential value-driving events for shareholders. For investors seeking exposure to late-stage neurodegenerative disease treatments with multiple near-term catalysts, NeuroSense's progress on both the pharmaceutical partnership and regulatory fronts presents a compelling opportunity to watch closely in the coming months. Recent News Highlights from NeuroSense NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment *Disclaimer: This article was written and published by Wall Street Wire™, a promotional content and distribution brand and network. Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. The operators of Wall Street Wire network are not registered brokers, dealers, or investment advisers. This article contains and is a form of paid promotional content related to NeuroSense Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This article has not been reviewed or approved by NeuroSense Therapeutics prior to publication. The information in this article is based on publicly available news reports and filings which have not been independently verified by us. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. Contact Details Wall Street Wire | Coverage Desk media.globalmarkets@gmail.com

April 24, 2025 10:36 AM Eastern Daylight Time

1 2 3 4 5 ... 312

Back